Overview

Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of colorectal cancer by stopping blood flow to the tumor. Giving thalidomide after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying surgery and thalidomide to see how well they work compared to surgery alone in treating patients with recurrent or metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)
Collaborator:
National Cancer Institute (NCI)
Treatments:
Thalidomide